Ostarine (MK-2866) and LGD-4033 (Ligandrol) are the two most extensively characterised selective androgen receptor modulators (SARMs) in the published scientific literature. Both were developed as investigational drugs targeting muscle wasting and bone density loss,...

Selective androgen receptor modulators (SARMs) occupy a distinct regulatory position in Australia — neither freely available consumer products nor entirely prohibited substances. Their legal status is determined by the Therapeutic Goods Administration (TGA) scheduling...

One of the most frequently researched parameters for MK-2866 (Ostarine) is its elimination half-life — the time required for plasma concentration to decrease by 50% following administration. This parameter has direct relevance to dosing interval design in clinical...